Vir Biotechnology Inc. navigates financial turbulence amidst strategic advancements, with its ECLIPSE program offering a beacon of hope for the company’s future prospects.

Vir Biotechnology Inc. navigates turbulent financial waters amidst promising developments in its chronic hepatitis B treatment, with preliminary data from the MARCH study showing potential for its therapeutic candidates.